RHJA
RCKT icon

Rice Hall James & Associates’s Rocket Pharmaceuticals RCKT Stock Holding History

Rice Hall James & Associates’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$330K Buy
96,469
+4,582
+5% +$15.2K 0.02% 228
2026
Q1 		$329K Buy
91,887
+6,900
+8% +$27.4K 0.02% 232
2025
Q4 		$298K Buy
84,987
+1,980
+2% +$6.78K 0.02% 233
2025
Q3 		$271K Sell
83,007
-9,391
-10% -$29.6K 0.01% 242
2025
Q2 		$226K Buy
92,398
+4,879
+6% +$24.7K 0.01% 245
2025
Q1 		$584K Sell
87,519
-3,315
-4% -$32.8K 0.03% 213
2024
Q4 		$1.14M Sell
90,834
-1,308
-1% -$19.7K 0.06% 199
2024
Q3 		$1.7M Buy
92,142
+16,719
+22% +$342K 0.09% 188
2024
Q2 		$1.62M Buy
75,423
+2,895
+4% +$66.5K 0.1% 178
2024
Q1 		$1.95M Buy
72,528
+100
+0.1% +$2.84K 0.11% 173
2023
Q4 		$2.17M Sell
72,428
-4,961
-6% -$109K 0.13% 166
2023
Q3 		$1.59M Sell
77,389
-1,597
-2% -$29K 0.1% 188
2023
Q2 		$1.57M Buy
78,986
+3,311
+4% +$66.9K 0.09% 191
2023
Q1 		$1.3M Buy
+75,675
New +$1.48M 0.07% 225

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Rice Hall James & Associates's RCKT Position: Q2 2026 in Review

Rice Hall James & Associates increased its Rocket Pharmaceuticals (RCKT) stake by 5% in Q2 2026, buying an estimated $15.2K and bringing the position to 96,469 shares worth $330K. The position accounts for 0.02% of the portfolio, ranked #228.

Rice Hall James & Associates first reported a position in RCKT in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.17M in Q4 2023. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Rice Hall James & Associates held 96,469 shares of Rocket Pharmaceuticals worth $330K as of Q2 2026.
  • Rice Hall James & Associates bought 4,582 Rocket Pharmaceuticals shares in Q2 2026, an estimated $15.2K.
  • Rocket Pharmaceuticals made up 0.02% of Rice Hall James & Associates's portfolio in Q2 2026, its #228 holding.
  • Rice Hall James & Associates first reported a position in Rocket Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • Rice Hall James & Associates's Rocket Pharmaceuticals position peaked at $2.17M in Q4 2023.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.